Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer emergency Supreme Court request

Executive Summary

Pfizer asks the Supreme Court May 29 to vacate the Federal Circuit U.S. Court of Appeals' ruling that its Norvasc patent is invalid until the court takes action on its concurrently filed petition for certiorari. The Federal Circuit denied Pfizer's request for an en banc review of its decision (1"The Pink Sheet" May 28, 2007, p. 23). Pfizer argues that the Federal Circuit "used a flawed analytical framework" in applying the Supreme Court's recent ruling in KSR v. Teleflex as to what constitutes an obvious patent...

You may also be interested in...

Federal Circuit Denies En Banc Review of Norvasc Decision

The pharmaceutical and biotech industries were dealt a blow when the Federal Circuit U.S. Court of Appeals decided not to reconsider its ruling that Pfizer's Norvasc (amlodipine besylate) patent is obvious

European Off-Patent Industry Decries Price Cuts And Clawbacks

A Medicines for Europe report on policies affecting the off-patent industry across 22 European countries aims to demonstrate the urgent need for pricing and reimbursement and procurement reforms.

MANTA Brings Glimmer Of Good News To Galapagos

After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts